Memorial Sloan Kettering Cancer Center
1275 York Avenue
New York
New York
10065
United States
203 articles about Memorial Sloan Kettering Cancer Center
-
The U.S. Senate Finance Committee and the House Oversight Committee started hearings on Tuesday, January 29, focused on dealing with high drug prices.
-
The U.S. government has been pushing to increase access to experimental drugs over the last two years. On August 18, 2018, the RACE for Children Act was signed into law as part of the 2017 FDA Reauthorization Act, which amended the Pediatric Research Equity Act (PREA).
-
This morning, Osaka, Japan-based Takeda struck deals with Memorial Sloan Kettering Cancer Center, Noile-Immune Biotech Inc. and Crescendo Biologics.
-
Many of these directors do not publicly disclose their affiliation with the pharma companies in their nonprofit biographies, report shows.
-
U.S./Australian Study Highlights Rapid Analysis and Clinical Utility of Liquid Biopsy Assay
11/28/2018
Resolution Bioscience's ctDx Lung cancer assay enhances patient treatment
-
Harvard Medical School and Brigham and Women’s Hospital are leading the call to remove the papers from the lab of Dr. Piero Anversa, a pioneer in the field of cardiac research.
-
Shares of Clovis Oncology are up more than 7 percent in premarket trading after the company announced positive results from a mid-stage clinical trial that showed patients treated with Rubraca achieved a 44 percent objective response rate in some patients with metastatic castration resistant pros...
-
Biotech Movers and Shakers for Oct. 8
10/8/2018
Transition continues as biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those transitions. -
Memorial Sloan Kettering's Chief Executive Officer Craig Thompson has resigned from the boards of directors at Merck and Charles River Labs as the cancer center continues to be scrutinized for its ties to the pharmaceutical industry.
-
Memorial Sloan Kettering CMO Steps Down Following His Failure to Disclose Financial Ties to the I...
9/14/2018
Days after a report by The New York Times and ProPublica revealed José Baselga, chief medical officer at Memorial Sloan Kettering Cancer Center, failed to disclose his vast financial ties to various companies in journal articles, the noted cancer researcher has resigned from his position. -
Noted Cancer Researcher Fails To Disclose Financial Ties to Pharma Companies in Published Articles
9/10/2018
José Baselga, chief medical officer at Memorial Sloan Kettering Cancer Center came under fire this weekend for his failure to disclose financial ties to various pharmaceutical companies when he published research papers in peer-reviewed journals. -
Movers and Shakers for Sept. 4
9/4/2018
Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let's take a look. -
By many standards, and certainly by the way the media covers it and industry promotes it, immuno-oncology therapies using CAR-T are revolutionizing cancer treatments. But what if, as the saying goes, they threw a revolution and nobody came? Or more precisely, what if they threw a revolution and n...
-
MabVax Therapeutics' HuMab-5B1 ImmunoPET Imaging Agent MVT-2163 Subject of National Institutes of Health R01 Research Grant Awarded to Memorial Sloan Kettering Cancer Center
7/6/2018
Grant intended to evaluate the utility of MVT-2163 to improve pre-operative staging of patients with pancreatic cancer
-
ITUS and Serametrix Announce Results of a Blinded Prostate Cancer Study
3/27/2018
Prostate cancer study with Serametrix in which data from a previous collaboration between Serametrix and Memorial Sloan Kettering Cancer Center (MSK) was re-evaluated using ITUS technology.
-
Personal Genome Diagnostics Expands Its Tumor Mutational Burden (TMB) Patent Portfolio for Cancer Immunotherapy
2/28/2018
Personal Genome Diagnostics Inc. (PGDx) today announced an agreement with Memorial Sloan Kettering Cancer Center (MSK) for developing, registering, and commercializing products and services that include tumor mutation burden (TMB) biomarker status.
-
Elekta Collaborates With Leading New York Cancer Center to Continue Development of Clinical Protocols for MR-linac Technology
2/27/2018
Elekta has entered into a research agreement with Memorial Sloan Kettering Cancer Center to investigate new treatment standards, imaging protocols, and treatment planning methodologies across various cancer indications.
-
Telix Pharmaceuticals and Memorial Sloan Kettering Cancer Center Announce Renal Cancer Collaboration
12/14/2017
The clinical objective is to use imaging as a precision medicine tool to rapidly determine an optimal therapeutic strategy for the patient.
-
Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration With Major Cancer Center in HER2-Mutated Cancer
12/13/2017
Daiichi Sankyo and Puma Biotechnology will co-sponsor the research.
-
PathoQuest Collaborating With Memorial Sloan Kettering Cancer Center to Study iDTECT Blood In Patients With Febrile Neutropenia
11/7/2017
iDTECT Blood is the only CE-IVD NGS-based test which offers a culture-free, agnostic metagenomic approach to improving the breadth of pathogen detection.